Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.
| Date |
Event |
People |
Places |
Sciences |
The drug, lecanemab, was approved under the FDA's Accelerated Approval pathway based on the results from a phase 3 trial. Developed by Eisai and Biogen, the drug targets amyloid beta, a toxic protein that builds up in the brains of Alzheimer's patients. It was evaluated in a double-blind, placebo-controlled, parallel group dose finding study of 856 patients with mild cognitive impairment or mild dementia stage of disease and confirmed presence of amyloid beta. 2023-01-26T00:00:00+0000| 26 Jan 2023 | | The US FDA approved the first monoclonal antibody for the treatment of Alzheimer's disease | Eisai, Biogen | Monoclonal antibodies, Alzheimer's |
Berg was an American biochemist. He first made his name in 1971 by demonstrating it was possible to insert DNA from a bacterium into the a virus' DNA, creating what is called recombinant DNA. This he did as part of his work to study viral chromosomes. He was awarded the Nobel Prize in 1980 for this work. His technique paved the way to the development of genetic engineering and the modern biotechnology industry. Berg was also instrumental in the setting up of the Asilomar Conference on Recombinant DNA, in 1975, which drew up the first guidelines for experiments with genetic engineering. 2023-02-15T00:00:00+0000| 15 Feb 2023 | | Paul Berg diedBerg | Stanford University | Recombinant DNA |
2,344,972 SARS-CoV-2 genomes sequenced by Wellcome Sanger Institute (15% of sequences uploaded to GISAID)2023-02-27T00:00:00+0000| 27 Feb 2023 | | 2,344,972 SARS-CoV-2 genomes sequenced by Wellcome Sanger Institute (15% of sequences uploaded to GISAID) | Wellcome Sanger Institute | Covid-19 |
|
Respond to or comment on this page on our feeds on Facebook, Instagram, Mastodon or Twitter.